TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Middle ear values of Tympanometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Middle ear ventilation evaluated by otoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic Stress Disorder Checklist-Civilian Version
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of group B streptococci in genital tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of colonizing extended-spectrum beta-lactamase enterobacteriaceae in genital tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Western Ontario and McMaster OA index (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American knee society knee score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK profile of MMF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds Ratio for Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrent disease
Endpoint domain: Adverse events/effects
Primary endpoint: Bleeding assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative hearing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numerical pain rating scale area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Achieving F-VASI35
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patients' perceptions, motivations, and expectations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-Time Curve (AUC) of 14C-Labeled Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of 14C-Labeled Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-Life (t1/2) of 14C-Labeled Vemurafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cumulative adhesion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of Chronic Venous Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Declarative Memory Measure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Validity of Carbon Dioxide angiography in Visualizing Renal and hypogastric arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Validity of Carbon Dioxide angiography in Visualizing Neck of the aneurysm measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Validity of Carbon Dioxide angiography in Visualizing Endoleaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Neuropathic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of global evoked auditory nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spectrum of global evoked auditory nerve activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cox Menstrual Symptom Scale (CMSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in bacterial colony count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Success (Achieving an End Infusion Peripheral Blood Methotrexate Concentration Between 50-80 μM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Horizontal Ridge Widths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fugl-Meyer Assessment of Upper Extremity (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm Motor Ability Test (AMAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Box and Blocks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative assessment of myocardial uptake of bone tracers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Exercise Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The incidence of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Problem Gambling Severity Index (PGSI) total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain and discomfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum plasma concentration observed (Cmax) of venglustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve calculated from time zero to the real time (tlast) (AUClast) of venglustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of venglustat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of circulating tumor DNA after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum dose constraint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune suppression during recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical global impression of the patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Image quality grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in identification of abnormalities (Standard OCT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in identification of abnormalities (OCTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned hospitalisation or emergency department visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants Still Breastfeeding at 20 Weeks Postpartum
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Odds of HIV Viral Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best objective response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of All-Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Major Amputation
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Clinically Driven Target Lesion Revascularization (CD-TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PK parameters for oral rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PK parameters for ethinylestradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PK parameters for levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Aggregate Cognitive Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: End tidal sevoflurane concentration at induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End tidal sevoflurane concentration for maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine use based on urine toxicology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD symptom severity based on the ADHD Rating scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Couple Satisfaction Index (CSI-4)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Reflux Symptom Index (RSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial plaque index (O'Leary index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic Therapeutic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Calgary Symptoms of Stress Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Dialyzer Clotting Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time reduction in seconds in the Time Up and Go (TUG) test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvements in morning prebronchodilator peak expiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: improvement in forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin surface moisture content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: caregiver-report of adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: youth-reported adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: fetal hemoglobin (HbF) lab values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean corpuscular volume (MCV) lab values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Medication Possession Ratio (MPR)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: pill count
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in tricuspid regurgitation at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Global Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CRS disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aesthetic Improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Aortic augmentation index (AIx)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NAD+ and related metabolite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shivering Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vineland scale standard scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hamilton Depression rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Resting state functional connectivity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: effects on nail mycology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appearance of diseased great toenails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased consumption of alcohol, tobacco or substances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative recovery assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DNA double strand break formations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic Skeletal Event-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: maximum tolerated dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with change of treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of post-hospital discharge complications
Endpoint domain: Adverse events/effects
Primary endpoint: number of ischemic cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite endpoint of neurologic injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite endpoint of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in wrinkle appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in appearance of skin pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self-reported physical well being
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Taste acceptability of ED
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in incidence of vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Change in incidence of pain
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Breast Cancer Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Immunologic Response as Measured by Peak Number of T Cells That Secrete IFNγ by ELISPOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Stent thrombosis (possible and probable)
Endpoint domain: Adverse events/effects
Primary endpoint: ALAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: ASAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: alkaline phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: gamma-glutamyltranspeptidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: SANS (Scale for the Assessment of Negative Symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI- Clinical Global Impression Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of exercise class attendance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of omeprazole
Endpoint domain: Adverse events/effects
Primary endpoint: Specific cellular immune response by Elispot and FACS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in the perception of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased intracranial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Metastatic involvement of second nodal echelon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: plasma concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of treatment emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Parkinson's symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameter for losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Symptoms Rated by the IPSS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma concentrations of DS-1093a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum erythropoietin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of Weaning Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of circulating Myeloid derived suppressor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall morbidity rate
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of logging into the portal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time spent in the portal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participant-reported utility of the portal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall survival (OS) in cisplatin-ineligible randomized participants
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival (OS) in PD-L1 positive (>=1%) randomized participants by immunohistochemistry (IHC)
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free survival (PFS) by blinded independent central review (BICR)
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival (OS) in cisplatin-eligible participants with previously untreated, unresectable or metastatic UC
Endpoint domain: Mortality/survival
Primary endpoint: Roland-Morris Low Back Pain and Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quadruple Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Heart rate and blood pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: graft failure requiring intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Neonatal Participants Admitted to the NICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of Treatment Abstinence Rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of SNPs of the DNase 1 and DNase gamma genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of AFP (IU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: tumor size or clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fugl Meyer Assessment-Upper Extremity Portion (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of hypotensive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with laboratory abnormalities related to treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Coronavirus-related catastrophizing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Subjective cognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in WOMAC Pain subscale average score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Patients who experience dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Correction of diastasis of the rectus abdominis muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Handgrip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-meter gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of abnormal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain/cramping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: ACT values after first injection of heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACT values after second injection of heparin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants With Treatment Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration Curve from time zero to the last quantifiable (AUC [0-last])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic pain threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with abnormal cerebral MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Interstitial fluid volume in the lower extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Clinical Asthma Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Species Richness Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes